ArticleAmerican journal of cancer research2026
Isorhamnetin from Astragalus membranaceus exerts anti-glioma effects via PI3K/Akt signaling pathway.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined the antitumor effects and molecular mechanisms of isorhamnetin in glioma treatment with a particular focus on its regulation of the PI3K/Akt signaling pathway, for developing targeted therapies. Using network pharmacology, we identified isorhamnetin could be used as a potential active ingredient in the regulation of glioblastoma (GBM) through the PI3K/Akt pathway. Bibliometric analysis was then used to review the current state and the developing trends in isorhamnetin research for anti-tumor applications. It was confirmed that isorhamnetin exerts its effects via the PI3K/Akt pathway. Our in vitro experiments showed further that isorhamnetin inhibits the proliferation and migration of glioma cells in a dose-dependent manner. Furthermore, isorhamnetin downregulated proteins related to the PI3K/Akt pathway, thereby suppressing its signaling activity. Isorhamnetin has antitumor effects against glioma by modulating the PI3K-Akt signaling pathway, providing experimental and mechanistic evidence for the potential use of isorhamnetin as a complementary GBM therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.